| Literature DB >> 29319460 |
Silvano Presciuttini1, Michele Curcio1, Rosalia Sciarrino1, Fabrizio Scatena1, Mark P Jensen2, Enrica L Santarcangelo1.
Abstract
The possible cooperation between hypnotizability-related and placebo mechanisms in pain modulation has not been consistently assessed. Here, we investigate possible genetic bases for such cooperation. The OPRM1 gene, which encodes the μ1 opioid receptor-the primary site of action for endogenous and exogenous opioids-is polymorphic in the general population for the missense mutation Asn40Asp (A118G, rs1799971). The minor allele 118G results in decreased levels of OPRM1 mRNA and protein. As a consequence, G carriers are less responsive to opioids. The aim of the study was to investigate whether hypnotizability is associated with the presence of the OPRM1 polymorphism. Forty-three high and 60 low hypnotizable individuals, as well as 162 controls, were genotyped for the A118G polymorphism of OPRM1. The frequency of the G allele was significantly higher in highs compared to both lows and controls. Findings suggest that an inefficient opioid system may be a distinctive characteristic of highs and that hypnotic assessment may predict lower responsiveness to opioids.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29319460 DOI: 10.1080/00207144.2018.1396128
Source DB: PubMed Journal: Int J Clin Exp Hypn ISSN: 0020-7144